AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15338488 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA therapy (prednisolone, methotrexate, and sulfasalazine)
Number of subjects: 155
Study 15338488 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (SSZ)
Number of subjects: 155
Study 15338488 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA therapy
Number of subjects: 155
Study 11919306 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg subcutaneously daily for 6 to 10 days followed by enoxaparin for another 21 days)
Number of subjects: 332
Study 11919306 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after initial enoxaparin treatment)
Number of subjects: 332
Study 11919306 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 332
Study 11919306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 332
Study 9613539 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-hole 27-gauge pencil-point needle
Number of subjects: 50
Study 9613539 — intervention group
Group type: COMPARATOR
Intervention: Double-hole 26-gauge pencil-point needle
Number of subjects: 50
Study 8087360 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiorphan (1.25 mg)
Number of subjects: 9
Study 8087360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2697584 — intervention group
Group type: COMPARATOR
Intervention: Melphalan and prednisone (MP)
Number of subjects: 13
Study 2697584 — intervention group
Group type: EXPERIMENTAL
Intervention: Various drug combinations
Number of subjects: 13
Study 2697584 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug combinations
Number of subjects: 13
Study 2697584 — intervention group
Group type: COMPARATOR
Intervention: Melphalan alone
Number of subjects: 13
Study 2697584 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of adriamycin, carmustine, cyclophosphamide, and melphalan
Number of subjects: 13
Study 794997 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (manual)
Number of subjects: 33
Study 794997 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (electrical)
Number of subjects: 33
Study 794997 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation with surface electrodes over acupuncture points
Number of subjects: 33
Study 794997 — intervention group
Group type: COMPARATOR
Intervention: Control (no acupuncture)
Number of subjects: 33
Study 31642145 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic and inelastic compression systems
Number of subjects: 45
Study 31642145 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID use
Number of subjects: 45
Study 30243503 — intervention group
Group type: EXPERIMENTAL
Intervention: PS-enriched beverage (2 g PS/day)
Number of subjects: 40
Study 30243503 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (without PS)
Number of subjects: 40
Study 28738295 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day simulation-based team training in obstetrics (12 units)
Number of subjects: 24
Study 28738295 — intervention group
Group type: COMPARATOR
Intervention: No team training (12 units)
Number of subjects: 24
Study 25323140 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 128
Study 25323140 — intervention group
Group type: COMPARATOR
Intervention: Medication (nortriptyline v. venlafaxine)
Number of subjects: 128
Study 24136634 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 256
Study 24136634 — intervention group
Group type: COMPARATOR
Intervention: Conventional self monitoring (Control)
Number of subjects: 256
Study 21654506 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CMH) 200 mg/kg daily for 6 months
Number of subjects: 18
Study 21654506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 19536164 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention offered as an adjunct to smoking cessation programmes
Number of subjects: 0
Study 19536164 — intervention group
Group type: COMPARATOR
Intervention: Nutritional intervention
Number of subjects: 0
Study 16762752 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes mellitus (T1DM)
Number of subjects: 88
Study 15310008 — intervention group
Group type: EXPERIMENTAL
Intervention: Dot-ELISA using PPF antigen
Number of subjects: 261
Study 15310008 — intervention group
Group type: COMPARATOR
Intervention: Micro-ELISA
Number of subjects: 261
Study 11429023 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR)
Number of subjects: 32
Study 11429023 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 32
Study 9121996 — intervention group
Group type: EXPERIMENTAL
Intervention: 6/6 ms waveform
Number of subjects: 31
Study 9121996 — intervention group
Group type: COMPARATOR
Intervention: 3/3 ms waveform
Number of subjects: 31
Study 8229908 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium loading (10 g/day)
Number of subjects: 18
Study 8229908 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 18
Study 3729085 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane (0.4%)
Number of subjects: 20
Study 3729085 — intervention group
Group type: COMPARATOR
Intervention: Control group (without enflurane)
Number of subjects: 20
Study 3729085 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 30236776 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted intervention (TP)
Number of subjects: 0
Study 30236776 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored counseling and navigation (TCN) intervention
Number of subjects: 0
Study 30236776 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study 26290275 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (n=26)
Number of subjects: 51
Study 26290275 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (n=25)
Number of subjects: 51
Study 24102822 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Belief Model-based nursing intervention
Number of subjects: 0
Study 24102822 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 0
Study 21224376 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg BID daily
Number of subjects: 37
Study 21224376 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE-MRI measurements (K(ep))
Number of subjects: 37
Study 21224376 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine analysis for bFGF
Number of subjects: 37
Study 16199916 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydropyridine calcium channel blockers
Number of subjects: 0
Study 16199916 — intervention group
Group type: COMPARATOR
Intervention: Calcium channel blockers
Number of subjects: 0
Study 11980131 — intervention group
Group type: EXPERIMENTAL
Intervention: Allicor 600 mg/day
Number of subjects: 85
Study 11980131 — intervention group
Group type: EXPERIMENTAL
Intervention: Allicor 2400 mg/day
Number of subjects: 85
Study 11980131 — intervention group
Group type: EXPERIMENTAL
Intervention: Kwai 900 mg/day
Number of subjects: 85
Study 11980131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 9481530 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5 mg elemental zinc in syrup daily for 12 weeks)
Number of subjects: 61
Study 9481530 — intervention group
Group type: COMPARATOR
Intervention: Placebo (syrup only)
Number of subjects: 61
Study 9481530 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 61
Study 7616798 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol 50 micrograms twice daily
Number of subjects: 17
Study 7616798 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study 2096042 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical anastomosis
Number of subjects: 140
Study 2096042 — intervention group
Group type: COMPARATOR
Intervention: Manual anastomosis
Number of subjects: 140
Study 2096042 — intervention group
Group type: COMPARATOR
Intervention: Terminolateral anastomosis with separate stitches
Number of subjects: 140
Study 25830 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 ml 100 proof vodka
Number of subjects: 12
Study 25830 — intervention group
Group type: COMPARATOR
Intervention: 180 ml water
Number of subjects: 12
Study 29480139 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0
Study 29480139 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 0
Study 27912934 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) treatment administered twice daily for 7-21 days, followed by TCM for AECOPD risk window over 28 days.
Number of subjects: 364
Study 27912934 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment administered according to the assigned group.
Number of subjects: 364
Study 27912934 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM treatment
Number of subjects: 364
Study 27912934 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 364
Study 27912934 — intervention group
Group type: COMPARATOR
Intervention: Both TCM and conventional treatments
Number of subjects: 364
Study 26241543 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosolvan (90 mg/day aerosol + 180 mg/day intravenous for 8 days)
Number of subjects: 0
Study 26241543 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 0
Study 23954450 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy
Number of subjects: 12816
Study 20938317 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week injury prevention course
Number of subjects: 76
Study 20938317 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard education)
Number of subjects: 76
Study 18262663 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0
Study 18262663 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 0
Study 18262663 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine D3 receptor antagonism
Number of subjects: 0
Study 18262663 — intervention group
Group type: EXPERIMENTAL
Intervention: New compounds targeting corticotropin‐releasing factor signalling and the endocannabinoid system
Number of subjects: 0
Study 16603599 — intervention group
Group type: EXPERIMENTAL
Intervention: DCb (docetaxel 75 mg/m(2), carboplatin AUC 6)
Number of subjects: 0
Study 16603599 — intervention group
Group type: COMPARATOR
Intervention: MIC/MVP (mitomycin 6 mg/m(2), ifosfamide 3 g/m(2) and cisplatin 50 mg/m(2) or mitomycin 6 mg/m(2), vinblastine 6 mg/m(2) and cisplatin 50 mg/m(2))
Number of subjects: 0
Study 12535320 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical class-based exercises for 8 months, 1 session of 60 min/week for 65 and 85 year-olds; 2 sessions/week for 75 year-olds.
Number of subjects: 3
Study 11008086 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (school-based program including reproductive health classes, the Postponing Sexual Involvement Curriculum, health risk screening, and booster activities)
Number of subjects: 582
Study 11008086 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 582
Study 11008086 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonintervention)
Number of subjects: 582
Study 11008086 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 582
Study 8902379 — intervention group
Group type: EXPERIMENTAL
Intervention: Supernormal DO2
Number of subjects: 0
Study 8902379 — intervention group
Group type: COMPARATOR
Intervention: Normal DO2
Number of subjects: 0
Study 8902379 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional assessment (gastric tonometer measurement of gastric mucosal PCO2 and pH)
Number of subjects: 0
Study 1450706 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha interferon (IFN, 3 MU daily for 10 days followed by 3 MU twice/week for 3 months)
Number of subjects: 55
Study 1450706 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 55
Study 6377983 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (IT)
Number of subjects: 87
Study 6377983 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IT)
Number of subjects: 87
Study 31570394 — intervention group
Group type: EXPERIMENTAL
Intervention: AT-527 600 mg once daily for seven days
Number of subjects: 0
Study 29534063 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS) tool for anticoagulant therapy adherence
Number of subjects: 8292
Study 29534063 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CDS intervention)
Number of subjects: 8292
Study 29534063 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS group
Number of subjects: 8292
Study 29534063 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8292
Study 27765693 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance for Parkinson's classes (N = 8)
Number of subjects: 15
Study 27765693 — intervention group
Group type: COMPARATOR
Intervention: PD support groups (N = 7)
Number of subjects: 15
Study 24180264 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Awareness Practices classes (n = 24) with home practice
Number of subjects: 47
Study 24180264 — intervention group
Group type: COMPARATOR
Intervention: Reading control condition (n = 23)
Number of subjects: 47
Study 24180264 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Mindfulness and Control)
Number of subjects: 47
Study 23070486 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilonacept (2.2 mg/kg, maximum 160 mg) by weekly subcutaneous injection for two 3-month courses
Number of subjects: 14
Study 23070486 — intervention group
Group type: COMPARATOR
Intervention: Placebo for two 3-month courses
Number of subjects: 14
Study 23070486 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilonacept
Number of subjects: 14
Study 23070486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 21073556 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 21073556 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 21073556 — intervention group
Group type: COMPARATOR
Intervention: Proton Pump Inhibitors (PPIs) like omeprazole and esomeprazole
Number of subjects: 0
Study 21073556 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs that do not interact with aspirin
Number of subjects: 0
Study 21073556 — intervention group
Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors
Number of subjects: 0
Study 19018918 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing intervention
Number of subjects: 284
Study 19018918 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 284
Study 16100136 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 240 mg IV once daily
Number of subjects: 24
Study 11852166 — intervention group
Group type: EXPERIMENTAL
Intervention: U.S. regulatory requirements for human subject protection
Number of subjects: 0
Study 11852166 — intervention group
Group type: EXPERIMENTAL
Intervention: Substudies within ESPRIT
Number of subjects: 0
Study 11852166 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes and experiences across countries regarding ethical issues
Number of subjects: 0
Study 11852166 — intervention group
Group type: EXPERIMENTAL
Intervention: Insight into U.S. regulatory processes
Number of subjects: 0
Study 9852390 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa + add-back therapy (20 microg of ethinyl estradiol with 0.15 mg desogestrel)
Number of subjects: 27
Study 9852390 — intervention group
Group type: COMPARATOR
Intervention: GnRHa + placebo
Number of subjects: 27
Study 7864265 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 60 mg/day)
Number of subjects: 101
Study 7864265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 2200195 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 269
Study 2200195 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 269
Study 2200195 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (radio- and chemotherapy with prospidine)
Number of subjects: 269
Study 2200195 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (vestibular cord cancer stage II)
Number of subjects: 269
Study 2200195 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (vestibular cord cancer stage II)
Number of subjects: 269
Study 2200195 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (vestibular cord cancer stage II)
Number of subjects: 269
Study 6986976 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 26
Study 6986976 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypophysectomy
Number of subjects: 26
Study 6986976 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (post-hypophysectomy phase)
Number of subjects: 26
Study 6986976 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequence of hypophysectomy followed by tamoxifen
Number of subjects: 26
Study 31733423 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (TPTD) 20 μg, s.c., once daily
Number of subjects: 60
Study 31733423 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous vertebroplasty (PVP) plus alendronate (70 mg, p.o., once weekly)
Number of subjects: 60
Study 31733423 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of TPTD treatment
Number of subjects: 60
Study 31733423 — intervention group
Group type: COMPARATOR
Intervention: Cost of PVP treatment
Number of subjects: 60
Study 31059579 — intervention group
Group type: EXPERIMENTAL
Intervention: Static cyclotorsion compensation (SCC) group
Number of subjects: 66
Study 31059579 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 28088167 — intervention group
Group type: EXPERIMENTAL
Intervention: ARMS-I (Halo™), sprayed intra-orally 3 times daily for 75 days
Number of subjects: 100
Study 28088167 — intervention group
Group type: EXPERIMENTAL
Intervention: ARMS-I (Halo™)
Number of subjects: 100
Study 28088167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 25449059 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled tiotropium 18 μg once daily for 1 month (n = 10)
Number of subjects: 20
Study 25449059 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment, n = 10)
Number of subjects: 20
Study 23706946 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 1185
Study 23706946 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 1185
Study 23706946 — intervention group
Group type: COMPARATOR
Intervention: Pro re nata dosing
Number of subjects: 1185
Study 23706946 — intervention group
Group type: COMPARATOR
Intervention: Genotype on 4 SNPs (rs1061170, rs10490924, rs11200638, rs2230199)
Number of subjects: 1185
Study 21381953 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally tubeless PCNL (group A)
Number of subjects: 70
Study 21381953 — intervention group
Group type: COMPARATOR
Intervention: Standard PCNL (group B)
Number of subjects: 70
Study 19080748 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive neurosurgery or intravenous hemostatics
Number of subjects: 0
Study 19080748 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized medical care according to ICH treatment guidelines
Number of subjects: 0
Study 19080748 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem cell therapy
Number of subjects: 0
Study 17173226 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg every 6 hours)
Number of subjects: 14
Study 14723798 — intervention group
Group type: EXPERIMENTAL
Intervention: CPB with hypothermia (mean 28 degrees C)
Number of subjects: 78
Study 14723798 — intervention group
Group type: COMPARATOR
Intervention: CABG with beating heart (no CPB) or peripheral vascular surgery with normothermia
Number of subjects: 78
Study 14723798 — intervention group
Group type: EXPERIMENTAL
Intervention: CPB with hypothermia and local ice‐slush application
Number of subjects: 78
Study 14723798 — intervention group
Group type: EXPERIMENTAL
Intervention: CPB with hypothermia
Number of subjects: 78
Study 11723779 — intervention group
Group type: EXPERIMENTAL
Intervention: ADCON-T/N
Number of subjects: 59
Study 11723779 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 59
Study 9602314 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (24 Gy in four fractions of 6 Gy)
Number of subjects: 74
Study 9602314 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 74
Study 8044597 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression stockings during surgery
Number of subjects: 40
Study 8044597 — intervention group
Group type: COMPARATOR
Intervention: No compression stockings during surgery
Number of subjects: 40
Study 2897978 — intervention group
Group type: EXPERIMENTAL
Intervention: Suriclone 0.8 mg
Number of subjects: 54
Study 2897978 — intervention group
Group type: COMPARATOR
Intervention: Suriclone 0.2 mg
Number of subjects: 54
Study 2897978 — intervention group
Group type: COMPARATOR
Intervention: Suriclone 0.4 mg
Number of subjects: 54
Study 2897978 — intervention group
Group type: COMPARATOR
Intervention: Suriclone 0.6 mg
Number of subjects: 54
Study 2897978 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 54
Study 31208412 — intervention group
Group type: EXPERIMENTAL
Intervention: Laquinimod
Number of subjects: 0
Study 31208412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29074128 — intervention group
Group type: EXPERIMENTAL
Intervention: Video double-lumen tube (VDLT)
Number of subjects: 80
Study 26826647 — intervention group
Group type: EXPERIMENTAL
Intervention: High cognitive load participants (n=425)
Number of subjects: 1018
Study 26826647 — intervention group
Group type: COMPARATOR
Intervention: Low cognitive load participants (n=593)
Number of subjects: 1018
Study 24783193 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-lipoxygenase (12-LOX) concentration in platelet-rich plasma
Number of subjects: 149
Study 24783193 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardization to thromboglobulin (TGB) and platelet count
Number of subjects: 149